56759-32-1

Usage

Uses

Used in Pharmaceutical Industry:
1-(4-AMINO-3-BROMO-PHENYL)-ETHANONE is used as a chemical intermediate for the synthesis of various pharmaceuticals and organic compounds. Its unique structure allows for the creation of new drugs and bioactive substances, contributing to the advancement of medicinal chemistry.
Used in Organic Chemistry Research:
In the field of organic chemistry, 1-(4-AMINO-3-BROMO-PHENYL)-ETHANONE serves as a key component in research and development. Its versatile structure enables the exploration of novel chemical reactions and the synthesis of complex organic molecules, furthering scientific understanding and innovation in organic chemistry.

InChI:InChI=1/C8H8BrNO/c1-5(11)6-2-3-8(10)7(9)4-6/h2-4H,10H2,1H3

Upstream product

• 101209-08-9 4-acetamido-3-bromoacetophenone 
• 99-92-3 p-aminobenzophenone 
• 107-21-1 ethylene glycol 
• 2719-21-3 4-(N-acetylamino)acetophenone 

Downstream Products

• 2142-63-4 1-(3-Bromophenyl)ethanone 
• 54826-14-1 1-(3-bromo-4-chlorophenyl)ethan-1-one 
• 93273-63-3 4-acetyl-2-bromobenzonitrile 
• 33720-71-7 4-amino-3-cyanoacetophenone 
• 954424-93-2 1-[4-Amino-3-(4,4-dimethyl-cyclohex-1-enyl)-phenyl]-ethanone 
• 940299-78-5 N-(4-acetyl-2-bromophenyl)-2,2,2-trifluoroacetamide 
• 1338440-28-0 8-acetylpyrido[1,2-a]benzimidazole 
• 1361186-28-8 C₁₉H₁₉NO₄ 
• 1395060-39-5 1-(4-amino-3-vinylphenyl)ethanone 
• 1428635-92-0 C₁₉H₂₁N₃OS 
• 1446427-41-3 C₂₆H₂₅N₃OS 
• 1446427-42-4 (E)-3-(4-chlorophenyl)-1-(2'-(methylthio)-6-((E)-pyrrolidin-1-yldiazenyl)-[1,1'-biphenyl]-3-yl)prop-2-en-1-one 
• 1446427-43-5 (E)-3-(4-methoxyphenyl)-1-(2'-(methylthio)-6-((E)-pyrrolidin-1-yldiazenyl)-[1,1'-biphenyl]-3-yl)prop-2-en-1-one 
• 1446427-44-6 (E)-1-(2'-(methylthio)-6-((E)-pyrrolidin-1-yldiazenyl)-[1,1'-biphenyl]-3-yl)-3-(p-tolyl)prop-2-en-1-one 

Relevant academic research and scientific papers

A Practical Procedure for Regioselective Bromination of Anilines

A highly practical procedure for the preparation of bromoanilines by using copper-catalyzed oxidative bromination has been developed. Treatment of free anilines with readily available NaBr and Na 2S 2O 8in the presence of a catalytic amount of CuSO 4·5H 2O enabled regioselective bromination.

Modular Synthesis of Di- A nd Trisubstituted Imidazoles from Ketones and Aldehydes: A Route to Kinase Inhibitors

A one-pot and modular approach to the synthesis of 2,4(5)-disubstituted imidazoles was developed based on ketone oxidation, employing catalytic HBr and DMSO, followed by imidazole condensation with aldehydes. This methodology afforded twenty-nine disubstituted NH-imidazoles (23%-85% yield). A three-step synthesis of 20 kinase inhibitors was achieved by employing this oxidation-condensation protocol, followed by bromination and Suzuki coupling in the imidazole ring to yield trisubstituted NH-imidazoles (23%-69%, three steps). This approach was also employed in the synthesis of known inhibitor GSK3037619A.

Phenylethanolamine β receptor agonist synthetic method

The invention discloses a phenylethanolamine β receptor agonist synthetic method, comprises the following steps: S1: the 4 - amino acetophenone dissolved in an organic solvent, with the electrophilic reagent occurs on the benzene ring substituted halogenated reaction, generating [...] intermediate; [...] intermediates in organic solvent or in water, under the catalysis of the metal catalyst with the cyanide reagent undergo nucleophilic substitution reaction, generating phenyl ketone intermediate; S2: phenyl ketone intermediates in organic solvent, with the copper bromide generating carbonyl α bromo reaction to produce α - bromoacetophenone intermediates; S3: α - bromoacetophenone intermediates in organic solvent with tert-butyl amine or isopropylamine reaction intermediates acetophenone amines; S4: acetophenone amine intermediates in organic solvent, with the reduction hydrogenation reagent react to generate the phenylethanolamine β receptor agonists; synthetic method of this invention a simple and highly efficient and cheap and easy to obtain, atom utilization is high, the synthetic product chemical purity is greater than 99%, to meet the detection requirements of the food safety.

Direct Synthesis of Structurally Divergent Indole Alkaloids from Simple Chemicals

A direct and structurally divergent synthesis of indole alkaloids from very simple 2-vinylanilines, alkynes and TBN via a novel substrate fragmentation/cycloaddition strategy has been developed, which provides an efficient noble-metal-free approach to access a library of highly valuable indole derivatives of tryptamines and tryptamine-related oximes, lactams, and lactones, as well as β-carbolines, spiroindolines, and hexa-hydropyrrolo[2,3-b]indoles.

Reducing Diastereomorphous Bis(phosphane oxide) Atropisomers to One Atropisomerically Pure Diphosphane: A New Ligand and a Novel Ligand-Preparation Design

1,1′-Biphenyl-2,2′-diphosphanes with an achiral bridge spanning C-5 and C-5′ form atropisomers that are enantiomers. Accessing them in an atropisomerically pure form requires resolving a racemic mixture thereof or of a bis(phosphane oxide) precursor. 1,1′-Biphenyl-2,2′-diphosphanes with a homochiral bridge spanning C-5 and C-5′ form atropisomers that are diastereomers. We synthesized the first compound of this kind 1) atropselectively and 2) under thermodynamic control—seemingly a first-time exploit in diphosphane synthesis. The selectivity-inducing step was a high-temperature reduction of two non-interconverting bis(phosphane oxide) atropisomers (60:40 mixture). It furnished the desired diphosphane atropisomerically pure (and atropconvergently because the yield was 67 %). This diphosphane proved worthwhile in Tsuji–Trost allylations, the Hayashi addition of phenylboronic acid to cyclohexenone, and the asymmetric hydrogenation of methyl acetoacetate (up to 95 % yield and 95 % ee).

PAN-GENOMIC INHIBITORS OF NS5A PROTEIN ENCODED BY HCV, PHARMACEUTICAL COMPOSITIONS, INTERMEDIATES FOR INHIBITOR SYNTHESIS, AND THEIR SYNTHESIS AND APPLICATION METHODS.

Compound represented by formula 1 : or a pharmaceutically acceptable salt, a hydrate, a crystalline form, or a stereoisomer thereof, wherein: where R11 is an optionally substituted C1-C6 alkyl, an optionally substituted C3-C6 cycloalkyl, or an optionally substituted C1-C6 alkyloxy, and arrows (1-C4alkyl; R3 is an optionally substituted aryl, an optionally substituted aryloxy, an optionally substituted arylsulfanyl, an optionally substituted arylamino, or an optionally substituted nitrogen hetaryl; where R41 is an optionally substituted C1-C6 alkyl, an optionally substituted C3-C6 cycloalkyl, or an optionally substituted C1-C6 alkyloxy; X is buta-1,3-diynylene or 1,4-phenylene; arrows (— ) indicate the position of substituents attachment.

Palladium(II)/N-Heterocyclic Carbene-Catalyzed Regioselective Heteroannulation of Tertiary Propargyl Alcohols and o-Haloanilines to form 2-Alkenylindoles

Monometallic and bimetallic palladium(II)/N-heterocyclic carbene complexes appended with naphthalimide or bisnaphthalimide moieties were designed, synthesized, and characterized. Employment of these catalysts brings about the step-economic and regioselective heteroannulation of tertiary propargyl alcohols with o-haloanilines resulting in biologically and pharmaceutically relevant 2-alkenylindoles. Basis for the regioselective heteroannulation is unraveled by coordination of the propargylic hydroxy moiety to palladium during insertion. Embracing this methodology, a single regioisomer of unsymmetrical 2,3-disubstituted indoles could be achieved through late-stage modification. The role of the naphthalimide or bisnaphthalimide appended to the NHC on the catalytic efficiency has been studied. (Figure presented.).

NOVEL AROMATIC COMPOUND AND USE THEREOF

Provided is a compound showing a bone formation promoting action (and/or bone resorption suppressive action). A compound of the formula (I) or a pharmacologically acceptable salt: [wherein each substituent is as defined in the DESCRIPTION], has low toxicity, shows good pharmacokinetics, has an action to promote bone formation, and is useful for the prophylaxis or To treatment of metabolic bone diseases (osteoporosis, fibrous osteitis (hyperparathyroidism), osteomalacia, Paget's disease that influences the systemic bone metabolism parameter etc.) associated with a decrease in the bone formation ability as compared to the bone resorption capacity.

Efficient synthesis of D6-clenproperol and D6-cimaterol using deuterium isopropylamine as labelled precursor

This report presents an efficient synthesis of D6-clenproperol and D6-cimaterol with 99.5% and 99.7% isotopic abundance in acceptable yields and excellent chemical purities with deuterium isopropylamine as labelled precursor. Their structures and the isotope-abundance were confirmed by proton nuclear magnetic resonance and liquid chromatography–mass spectrometry.

Synthesis of stable isotope labeled D9-Mabuterol, D9-Bambuterol, and D9-Cimbuterol

Three stable and simple synthetic routes of labeled D9-Mabuterol, D9-Bambuterol, and D9-Cimbuterol were described with 98.5%, 99.7%, and 98.4% isotopic abundance and good purity. These structures and isotope-abundance were confirmed according to 1H NMR and liquid chromatography-tandem mass spectrometry.